P
P

Pfizer

交易方向

交易者脈動

技術摘要

小時

財經新聞

CureVac may let contractors make rival vaccines if own shot fails -CEO

By Tilman Blasshofer and Ludwig Burger FRANKFURT, June 17 (Reuters) - German biotech firm CureVac 5CV.DE could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday. The German company saw billions of euros wiped
B
G
N
P
W

Vaccine delivery delays to Norway no threat to economy, central bank chief says

OSLO, June 17 (Reuters) - Announced delays in vaccine deliveries to Norway in the third quarter do not affect the central bank's view of the country's economic recovery, Norges Governor Oeystein Olsen told Reuters on Thursday. "The information (about delays with Pfizer/BioNTech vaccine deliveries) doesn't shift the big picture," Olsen said in an in
P

Australia limits use of AstraZeneca 19 vaccine to people over 60

SYDNEY/CANBERRA, June 17 (Reuters) - Australia will recommend only people over 60 receive AstraZeneca's AZN.L COVID-19 vaccine, the country's Minister for Health Greg Hunt said on Thursday, following a spate of blood clots in those who have received the inoculation. Australia has administered 3.3 million doses of the AstraZeneca vaccine, and it has
A
P

Australia recommends AstraZeneca 19 vaccine only for people over 60

SYDNEY, June 17 (Reuters) - Australia will recommend AstraZeneca AZN.L COVID-19 vaccines only for people aged 60 years and over, while Pfizer PFE.N shots will be offered to others, Health Minister Greg Hunt said on Thursday. Australia said in early April they would recommend people under 50 should get Pfizer's vaccine in preference to AstraZeneca d
A
P

Australia panel to recommend AstraZeneca vaccines only for above 60s-media

SYDNEY, June 17 (Reuters) - Australia's expert immunisation panel would recommend restricting the use of AstraZeneca's AZN.L COVID-19 vaccine only to people over 60, Australian media reported on Thursday. Australia's state and territory leaders have been informed about the recommendation from the Australian Technical Advisory Group on Immunisation
A
P

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示: 您的資金存在風險。杠杆商品可能不適合所有客戶。 請詳細閱讀我們的風險聲明